Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GBL bill

This article was originally published in The Tan Sheet

Executive Summary

House passes the Hillary J. Farias Date-Rape Prevention Drug Act Oct. 12 by a vote of 423-1. The bill (HR 2130) would classify both gamma butyrolactone and gamma hydroxybutyric acid as controlled substances; it passed the House Commerce Committee by voice vote Aug. 5 (1"The Tan Sheet" Aug. 16, In Brief). Companion legislation introduced in the Senate by Spencer Abraham (R-Mich.) is expected to be the subject of a hearing in the next 10 to 14 days. GBL, sold as a dietary supplement, has been the subject of several FDA warnings; GHB is under scrutiny as a "date rape" drug

You may also be interested in...



GBL

Hillary J. Farias Date Rape Prevention Drug Act (HR 2130) passes the full House Commerce Committee by voice vote Aug. 5. The bill, which would classify both gamma butyrolactone and gamma hydroxybutyric acid as controlled substances, passed the Commerce/Health Subcommittee July 27 (1"The Tan Sheet" Aug. 2, p. 4). The bill should reach the House floor in the weeks following Labor Day. Sen. Spencer Abraham (R-Mich.) introduced companion legislation (S 1561) Aug. 5, which was referred to the Judiciary Committee

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS090441

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel